MedPath

Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing

Not Applicable
Completed
Conditions
Ventilator Induced Diaphragm Dysfunction
Interventions
Device: Diaphragmatic Pacing Therapy DPTS
Registration Number
NCT03096639
Lead Sponsor
Lungpacer Medical Inc.
Brief Summary

A randomized clinical trial to investigate the use of the temporary Diaphragm Pacing Therapy System (DPTS) to rehabilitate the diaphragm in mechanically ventilated patients who have failed at least two weaning attempts. The goal is to strengthen and rehabilitate the diaphragm to liberate the patient more quickly from mechanical ventilation.

Detailed Description

Mechanical ventilation (MV) is a life saving technology but can also cause damage to the lungs and diaphragm such as ventricular induced diaphragmatic dysfunction (VIDD). Research has shown that after being on mandatory MV and sedated the diaphragm begins to atrophy within as short as 18 hours. The Lungpacer Diaphragm Pacing Therapy System (DPTS) is a temporary therapy that consists of the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) and the Lungpacer Control Unit system. The LIVE Catheter is a proprietary central venous catheter that incorporates pacing electrodes in strategic areas that align with the left and right phrenic nerves. The LIVE Catheter can also be used for fluid delivery like any other central venous catheter. The randomized clinical trial will investigate the safety, effectiveness and performance of the Lungpacer DPTS. By stimulating the diaphragm through daily therapy sessions, with the intention of exercising and rehabilitating the diaphragm muscle so the patient may be able to be more quickly liberated from MV. The patient population includes those who have been mechanically ventilated for greater than or equal to 96 hours (4days), have failed two or more spontaneous breathing trials (SBT), and were not hypervolemic during the latest spontaneous breathing trial. Patients must have resolution of the initial indication for placement on mechanical ventilation before entering the trial.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
110
Inclusion Criteria
  • 18 years of age or older
  • have been mechanically ventilated for > or = to 96 hours (4 days), and
  • have satisfied the Readiness-to-Wean criteria and
  • have failed at least two VLTs, one of which is the study specific VLT.
Exclusion Criteria
  • currently on extracorporeal membrane oxygenation (ECMO);
  • weaning failure due to hypervolemia;
  • medical history or known anatomy that prevents insertion of the LIVE Catheter into the left subclavian vein;
  • currently being treated with neuromuscular blockade;
  • clinically overt congestive heart failure that is preventing weaning;
  • pre-existing neuromuscular diseases that could affect the respiratory muscles;
  • pre-existing severe chronic pulmonary fibrosis;
  • pleural effusions occupying greater than one third of the pleural space on either side;
  • BMI > or = 40;
  • known or suspected phrenic nerve paralysis;
  • any electrical device (implanted or external) that may be prone to interaction with or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators;
  • prior bacteremia reported within the last 48 hours;
  • current hemodynamic instability, sepsis or septic shock;
  • terminally ill with 6 months or less life expectancy or not committed to full care;
  • known or suspected to be pregnant or lactating; and
  • currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Diaphragm Pacing Therapy DPTSDiaphragmatic Pacing Therapy DPTSDiaphragm Pacing intervention will be conducted 2x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.
Primary Outcome Measures
NameTimeMethod
Proportion successfully weaned by 30 days for subjects randomized to Treatment (Lungpacer DPTS) as compared to subjects randomized to Control.Patients will be allowed to stay in the study for up to 30 (+2 days of follow up for adverse events) days if not removed from mechanical ventilation sooner

"Successfully weaned" is defined as passing the protocol-specific Ventilator Liberation Trial (VLT), or removed from MV, and not reintubated (subjects with an oral or nasal, endotracheal tube) or returned to MV (subjects with a tracheostomy) within 48 hours

Secondary Outcome Measures
NameTimeMethod
Changes in MIPto successful weaning, or on day 30, whichever comes first.

Change in MIP from randomization to last available measure; Change in MIP over time from randomization (baseline).

Days on mechanical ventilationfrom randomization to 30 days

Days on mechanical ventilation from randomization to removal from MV associated with successful weaning or Day 30, whichever comes first

Mortalityon day 30

30-day mortality

Changes in diaphragmatic thickening fraction on diaphragm ultrasoundto successful weaning or on day 30 which ever comes first.

Evaluate difference in changes in diaphragmatic thickening fraction between study allocation groups from randomization to successful weaning or on day 30 whichever comes first;

Change in MIPto successful weaning, or on day 30 whichever comes first.

Rate of MIP change per day from randomization (baseline) to last available measure;

Changes in RSBIto successful weaning, or on day 30, whichever comes first

Change in RSBI from randomization (baseline) to last available measure; Change in RSBI over time from randomization (baseline);

Change in RSBIto successful weaning, or on day 30, whichever comes first

Rate of RSBI change per day from randomization (baseline) to last available measure;

Trial Locations

Locations (21)

CHU Angers, Reanimation Medicale

🇫🇷

Angers, France

Hopital Louis-Mourier

🇫🇷

Colombes, France

CHU Montpellier

🇫🇷

Montpellier, France

Hopital Europeen Georges-Pompidou

🇫🇷

Paris, France

Pitie Salpetriere Hospital

🇫🇷

Paris, France

Uniklinik RWTH Aachen

🇩🇪

Aachen, Germany

Heart and Diabetes Center Bad Oeynhausen

🇩🇪

Bad Oeynhausen, Germany

Universitatsklinikum Bonn

🇩🇪

Bonn, Germany

Universitatsklinik Dresden

🇩🇪

Dresden, Germany

Universitatsmedizin Gottingen, Georg-August-Universitat

🇩🇪

Gottingen, Germany

Asklepios Kliniken Hamburg GmbH - Asklepios Klinikum Harburg

🇩🇪

Hamburg, Germany

Universitätsklinikum Hamburg-Eppendorf (UKE)

🇩🇪

Hamburg, Germany

Fachkrankenhaus Kloster Grafschaft

🇩🇪

Schmallenberg, Germany

Med Uni-Heidelberg

🇩🇪

Heidelberg, Germany

Universitätsklinikum Jena

🇩🇪

Jena, Germany

Universitatsklinikum Regensburg

🇩🇪

Regensburg, Germany

Klinikum Nuernberg

🇩🇪

Nuernberg, Germany

Wissenschaftliches Institut Bethanien fur Pneumologie e.V.

🇩🇪

Solingen, Germany

Centre Hospitalier Universitaire de Nice (CHU Nice)

🇫🇷

Nice, France

Centre Hospitalier Universitaire CHU

🇫🇷

Strasbourg, France

Charite Universitatsmedizin Berlin - Mitte campus

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath